Persistent monosomy 7 in Philadelphia chromosome-negative cells without disease progression over nearly two decades of follow-up in chronic myeloid leukemia.
Monosomy 7 (-7) is frequently associated with myelodysplastic neoplasm/syndrome (MDS) and acute myeloid leukemia (AML).
APA
Chen M, Tang G, Hu S (2026). Persistent monosomy 7 in Philadelphia chromosome-negative cells without disease progression over nearly two decades of follow-up in chronic myeloid leukemia.. Cancer genetics, 302-303, 73-78. https://doi.org/10.1016/j.cancergen.2026.01.010
MLA
Chen M, et al.. "Persistent monosomy 7 in Philadelphia chromosome-negative cells without disease progression over nearly two decades of follow-up in chronic myeloid leukemia.." Cancer genetics, vol. 302-303, 2026, pp. 73-78.
PMID
41579782
Abstract
Monosomy 7 (-7) is frequently associated with myelodysplastic neoplasm/syndrome (MDS) and acute myeloid leukemia (AML). In chronic myeloid leukemia (CML), the acquisition of -7 in Philadelphia chromosome-positive (Ph-positive) cells is considered a high-risk feature for progression to blast crisis. However, the clinical significance of -7 in Ph-negative cells remains less unclear. We report a patient with CML who developed a - 7 clone in Ph-negative cells during tyrosine kinase inhibitor (TKI) therapy. The -7 clone emerged after 14 months of TKI treatment, persisted for nearly six years, and subsequently disappeared. The patient continued treatment with sequential TKIs under long-term surveillance. Over nearly 20 years of follow-up, there was no evidence of significant dysplasia or progression to AML. This case suggests that the occurrence of -7 in Ph-negative cells does not reflect TKI-induced genotoxicity and does not necessarily confer an increased risk of MDS or AML.
MeSH Terms
Humans; Chromosomes, Human, Pair 7; Disease Progression; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Follow-Up Studies; Philadelphia Chromosome; Male; Chromosome Deletion; Middle Aged
같은 제1저자의 인용 많은 논문 (5)
- A radio-genomics biomarker for precision epidermal growth factor receptor mutation targeting therapy in non-small cell lung cancer.
- SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia.
- Artificial intelligence in colon cancer: A commentary on advances and challenges.
- Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes.
- Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.